Major institutional moves, such as Soros Fund Management cutting its stake by nearly 16% in late 2025, signal a lack of confidence in a quick turnaround. The Bull Case: Deep Value and Long-Term Recovery
The company’s net profit margin sat at a razor-thin 0.92% at the end of 2025. Rising medical utilization and relatively flat government reimbursement rates continue to squeeze profitability. humana stock buy or sell
Humana Inc. (HUM) is currently navigating a period of significant transition as of late April 2026. While its stock has faced immense pressure—trading around , down from year-ago highs of approximately $315 —the investment case for Humana is a complex tug-of-war between immediate structural headwinds and a long-term recovery thesis. The Bear Case: Structural Pressures in 2026 Major institutional moves, such as Soros Fund Management